5-MeO-DMT is Unscheduled at the Federal Level in the United States. However, this is a gray area in the drug laws. 5-MeO-DMT is an analog of Bufotenine, which is Schedule I, and may be covered under the Analog Act.
Addictive Potential: None
Emergency Room Visits Yearly: Unknown
Mandatory Minimum Sentence: None
Mechanism of Action: Increases the Neurotransmitter Serotonin
5-MeO-DMT is a very powerful psychedelic tryptamine. It is found in a wide variety of plant species and the Bufo Alvarius toad, and like its close relative DMT, it has been used as an entheogen by South American shamans for thousands of years.
5-MeO-DMT was first synthesized in 1936. In 1959, it was isolated as one of the psychoactive ingredients of Anadenanthera peregrina seeds used in Yopo snuff. It occurs in many organisms that contain bufotenine (5-hydroxy-DMT), and is the O-methyl analogue of that compound.
It is active when smoked, insufflated, injected IV, or combined with an MAOI.
Currently, Nebraska and South Dakota have classified 5-MeO-DMT as Schedule I at the state level.
First person charged for possession of 5-MeO-DMT under the Analog Act: In 2009-2010, Patrick Malloy was charged with possession of 5-MeO-DMT in the circuit court of the sixteenth judicial circuit in Kane county Illinois (docket- 09CF2059). He was placed on two years felony probation in Kane county with a withheld judgement, although, it shows on his record as a conviction. He served no jail time on the case.
|Ehrlich’s Reagent||Marquis Reagent|
|5-MeO-DMT||purple to blue||yellow to black|
(Info provided by DEA, 2005)